The Michael J. Fox Foundation (MJFF) encouraged the U.S. House of Representatives’ Committee on Veterans’ Affairs to expand healthcare access for veterans exposed to hazardous chemicals, and to better support research into service-connected Parkinson’s disease. Recently, the committee hosted a roundtable discussion about healthcare costs for veterans exposed…
Medications used to treat rheumatoid arthritis, an autoimmune disorder, do not affect a person’s risk of developing Parkinson’s disease, a Finnish study, funded by the Michael J. Fox Foundation for Parkinson’s Research, reported. Rheumatoid arthritis has been associated with a lower Parkinson’s risk, but exposure to arthritis therapies did…
A short course of ENT-01, Enterin’s investigational therapy for Parkinson’s disease, appears to restore the function of nerve cells found in the gut to ease constipation. These findings come from KARMET, a Phase 2b clinical trial (NCT03781791) that evaluated ENT-01’s safety when taken once daily for at…
Caraway Therapeutics was awarded a new research grant from the Michael J. Fox Foundation (MJFF) to further work on therapies that increase flux, or movement, into the lysosome, a tiny cell compartment that helps clear away the alpha-synuclein toxic clumps that are known to cause Parkinson’s disease. This…
South Carolina’s Integrated Micro-Chromatography Systems (IMCS) has been awarded a $1.8-million grant to advance the development of affordable gangliosides — fat molecules with a sugar link — to aid in developing therapeutics and diagnostics for Parkinson’s and other neurological diseases. The funds are part of a second parcel of…
Athira Pharma has dosed the first patient in its Phase 2 clinical trial evaluating ATH-1017 as a treatment for Parkinson’s disease dementia (PDD) and dementia with Lewy bodies (DLB) — forms of more severe cognitive impairment in Parkinson’s disease. The trial (NCT04831281), known as SHAPE, is still…
Some people with Parkinson’s disease find that using cannabis products helps to ease certain symptoms, according to results from a survey. The findings notably suggest that cannabis products with high levels of the chemical THC are more likely to induce both positive and negative effects in Parkinson’s patients. “These…
The U.S. Food and Drug Administration (FDA) has given positive feedback to Annovis Bio’s plans to start two Phase 3 clinical trials of buntanetap (ANVS401) as an oral therapy for early- and late-stage Parkinson’s disease. The feedback followed a review of data from a Phase 2 clinical trial showing significant…
Zhittya Genesis Medicine is hosting a webinar next week to provide information about the recently announced “Compassionate Use Clinical Trial” of the company’s lead therapy for Parkinson’s disease. The webinar is taking place on Tuesday, Feb. 1, at 3 p.m. Pacific time (6 p.m. Eastern). Registration is…
Lundbeck, with support from the Michael J. Fox Foundation (MJFF), is working to develop a “state of the art” biomarker test that could diagnose neurodegenerative diseases like Parkinson’s in early stages. The test, or assay, being developed in collaboration with scientists at the Danish Technical University (DTU) may also…
Get regular updates to your inbox.
